Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Varenicline for tobacco dependence.

× No keyword cloud information.

30 in total

1. Varenicline-induced manic episode in a patient with bipolar disorder.

Authors: Izchak Kohen; Neil Kremen
Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112

2. Exacerbation of schizophrenia by varenicline.

Authors: Robert Freedman
Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112

3. Smoking and suicidal behaviors in the National Comorbidity Survey: Replication.

Authors: Ronald C Kessler; Patricia A Berglund; Guilherme Borges; Ruby C Castilla-Puentes; Meyer D Glantz; Savina A Jaeger; Kathleen R Merikangas; Matthew K Nock; Leo J Russo; Paul E Stang
Journal: J Nerv Ment Dis Date: 2007-05 Impact factor: 2.254

4. A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

Authors: Kathryn E Williams; Karen R Reeves; Clare B Billing; Ann M Pennington; Jason Gong
Journal: Curr Med Res Opin Date: 2007-04 Impact factor: 2.580

5. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Authors: Cheryl Oncken; David Gonzales; Mitchell Nides; Stephen Rennard; Eric Watsky; Clare B Billing; Richard Anziano; Karen Reeves
Journal: Arch Intern Med Date: 2006 Aug 14-28

6. Cigarette smoking among adults--United States, 2006.

Authors:
Journal: MMWR Morb Mortal Wkly Rep Date: 2007-11-09 Impact factor: 17.586

7. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).

Authors: Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina
Journal: Eur Heart J Date: 2007-08-28 Impact factor: 29.983

8. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

Authors: Shih-Tzu Tsai; Hong-Jun Cho; Huey-Shinn Cheng; Cheol-Hwan Kim; Kuang-Chieh Hsueh; Clare B Billing; Kathryn E Williams
Journal: Clin Ther Date: 2007-06 Impact factor: 3.393

9. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

Authors: Masakazu Nakamura; Akira Oshima; Yoko Fujimoto; Nami Maruyama; Taro Ishibashi; Karen R Reeves
Journal: Clin Ther Date: 2007-06 Impact factor: 3.393

Review 10. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.

Authors: Ping Wu; Kumanan Wilson; Popey Dimoulas; Edward J Mills
Journal: BMC Public Health Date: 2006-12-11 Impact factor: 3.295

30 in total

1. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.

Authors: Mira Harrison-Woolrych; Simran Maggo; Ming Tan; Ruth Savage; Janelle Ashton
Journal: Drug Saf Date: 2012-01-01 Impact factor: 5.606

2. [Risk factor "smoking" : smoking cessation in patients with cardiovascular diseases].

Authors: J Weil; J Stritzke; H Schunkert
Journal: Internist (Berl) Date: 2012-01 Impact factor: 0.743

Review 3. Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

Authors: Robert D Gibbons; J John Mann
Journal: Drug Saf Date: 2011-05-01 Impact factor: 5.606

4. Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are associated with nicotine and opioid dependence severity.

Authors: Porat M Erlich; Stuart N Hoffman; Margaret Rukstalis; John J Han; Xin Chu; W H Linda Kao; Glenn S Gerhard; Walter F Stewart; Joseph A Boscarino
Journal: Hum Genet Date: 2010-08-20 Impact factor: 4.132

Varenicline for tobacco dependence.

1. Varenicline-induced manic episode in a patient with bipolar disorder.

2. Exacerbation of schizophrenia by varenicline.

3. Smoking and suicidal behaviors in the National Comorbidity Survey: Replication.

4. A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

5. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

6. Cigarette smoking among adults--United States, 2006.

8. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

9. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

Review 10. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.

1. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.

2. [Risk factor "smoking" : smoking cessation in patients with cardiovascular diseases].

Review 3. Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

4. Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are associated with nicotine and opioid dependence severity.

Review 5. Designation of obesity as a disease: lessons learned from alcohol and tobacco.

Review 6. The biology and management of non-small cell lung cancer.

7. The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.

8. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.

Review 9. Chronic obstructive pulmonary disease: an update on diagnosis and management issues in older adults.

10. Varenicline-induced psychotic depressive episode in a patient with bipolar disorder.